ArticleMedical microbiology and immunology2009
Inhibition of HBV infection by bovine lactoferrin and iron-, zinc-saturated lactoferrin.
Article in Medical microbiology and immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy.Hepatology international · 2022Guideline
- Milk Antiviral Proteins and Derived Peptides against Zoonoses.International journal of molecular sciences · 2024Review
- Article
- Nutraceutical and Health-Promoting Potential of Lactoferrin, an Iron-Binding Protein in Human and Animal: Current Knowledge.Biological trace element research · 2024Review
- Activity Changes of the Peptic Lactoferrin Hydrolysate in Human Gastric Cancer AGS Cells in Response to Cu(II) or Mn(II) Addition.Foods (Basel, Switzerland) · 2023Article
- Transchromosomic bovines-derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARS-CoV-2, MERS-CoV, Ebola, Zika, HIV-1, and influenza A virus.Journal of medical virology · 2022Review
- Article
- Regulation of zinc-dependent enzymes by metal carrier proteins.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2022Review
- Antiviral properties of whey proteins and their activity against SARS-CoV-2 infection.Journal of functional foods · 2022Review
- Role of milk glycome in prevention, treatment, and recovery of COVID-19.Frontiers in nutrition · 2022Review
- Protective Action ofMaterials (Basel, Switzerland) · 2021Article
- Potential "biopeptidal" therapeutics for severe respiratory syndrome coronaviruses: a review of antiviral peptides, viral mechanisms, and prospective needs.Applied microbiology and biotechnology · 2021Review
- Immune-Boosting, Antioxidant and Anti-inflammatory Food Supplements Targeting Pathogenesis of COVID-19.Frontiers in immunology · 2020Review
- Antiviral peptides as promising therapeutic drugs.Cellular and molecular life sciences : CMLS · 2019Review
- Review
- Effect of Cu/Mn-Fortification on In Vitro Activities of the Peptic Hydrolysate of Bovine Lactoferrin against Human Gastric Cancer BGC-823 Cells.Molecules (Basel, Switzerland) · 2019Article
- Individualized management of pregnant women with high hepatitis B virus DNA levels.World journal of gastroenterology · 2014Review
- Chronic hepatitis B virus infection and pregnancy.Journal of clinical and experimental hepatology · 2012Review
- Antiviral properties of lactoferrin--a natural immunity molecule.Molecules (Basel, Switzerland) · 2011Review
- Breastfeeding and chronic HBV infection: clinical and social implications.World journal of gastroenterology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we investigated the effect of bovine lactoferrin (BLf), lactoferrin hydrolysate, or iron-, zinc-saturated lactoferrin on hepatitis B virus (HBV)-infected HepG2 cells. Fluorescent quantitative polymerase chain reaction (FQ-PCR) was used to quantify HBV-DNA copies. BLf, iron- or zinc-saturated lactoferrin significantly inhibited the amplification of HBV-DNA in a dose-dependent manner in HBV-infected HepG2 cells. However, the inhibitive effect of lactoferrin hydrolysate on HBV-DNA copies was insignificant. These findings suggest that BLf inhibits the function of HBV by integrated structure. In conclusion, BLf, iron- or zinc-saturated BLf is one of the candidates for anti-HBV reagents in treatment of patients with hepatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.